171 Axonal Loss in Narcolepsy Type 1 Table 2: Continued. Donor ID Sex Age (year) PMD (year) Disease duration (year) CSF-pH Brain weight (gram) HCRT cells (count) Braak NFT stage Amyloid stage Braak LB stage Cause of death Relevant medication Control 4 Female 84 5.6 N/A 6.7 1,027 23,716 2 A 0 Heart failure Gabapentin, oxycodone, haloperidol Control 5 Male 88 4.7 N/A 6.2 1,418 31,013 2 A 0 Gastrointestinal bleeding - Control midbrain 1 Female 69 6.3 N/A 6.6 1,229 N/A 1 N/A 0 Cardiogenic shock Levothyroxine, lorazepam Control midbrain 2 Female 71 6.3 N/A N/A 1,175 N/A 2 N/A N/A Heart failure Duloxetine, fentanyl, codeine, pregabaline, quetiapine, temazepam, zopiclone Control midbrain 3 Female 82 5.3 N/A 6.3 1,221 N/A 2 B N/A Thoracic aortic dissection Levothyroxine, temazepam Control midbrain 4 Female 85 7.1 N/A N/A 1,007 N/A 1 B 0 Terminal renal insufficiency Clonazepam, diazepam, amitriptyline, morphine, zopiclone, tramadol, pramipexol, fentanyl, midazolam 6
RkJQdWJsaXNoZXIy MjY0ODMw